Novartis AG Says FDA Approves Menveo Vaccination in Children, Not Infants

January 31, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- U.S. regulators approved Novartis AG’s Menveo meningococcal vaccine for use in children from 2 years of age, though they requested more information on use of the shot in infants.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals

Food and Drug Administration (FDA) Novartis